Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ImmunityBio Inc. is conducting a study titled ‘Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID.’ The study aims to assess the safety and effectiveness of Anktiva in treating Long COVID, characterized by persistent symptoms post-COVID-19 infection. This research is significant as it addresses ongoing health challenges faced by COVID-19 survivors.
The intervention being tested is Anktiva, a drug administered subcutaneously at a dose of 600ug. Anktiva is designed to alleviate symptoms associated with Long COVID, potentially offering relief to patients suffering from prolonged effects of the virus.
The study is interventional, with a single-group assignment and no masking, focusing primarily on treatment. This straightforward design allows for direct observation of Anktiva’s effects on participants.
Key dates for the study include an estimated start in August 2025, with the primary completion and overall completion dates yet to be determined. The last update was submitted on August 13, 2025, indicating that the study is actively recruiting participants.
This study update could influence ImmunityBio’s stock performance positively if Anktiva proves effective, as it would position the company as a leader in addressing Long COVID. Investor sentiment may be buoyed by the potential market for Long COVID treatments, although competition in the biopharmaceutical industry remains intense.
The study is ongoing, with further details available on the ClinicalTrials portal.